Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date
|
|
- Marjorie Wendy Armstrong
- 5 years ago
- Views:
Transcription
1 Diltiazem Hydrochloride Extended-Release Capsules Type of Posting Posting Date Official Date Revision Bulletin 17 Nov Dec 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance In accordance with the Rules and Procedures of the Council of Experts, the Monographs Chemical Medicines 2 Expert Committee has revised the Diltiazem Hydrochloride Extended-Release Capsules The purpose for the revision is to add Dis Test 18 to accommodate the FDA approved drug products with different dis conditions and tolerance than the existing dis test The Diltiazem Hydrochloride Extended-Release Capsules Revision Bulletin supersedes the currently official Diltiazem Hydrochloride Extended-Release Capsules The Revision Bulletin will be incorporated in the Second Supplement to USP 41 NF 36 Should you have any questions, please contact Edith Chang, Scientific Liaison ( or yec@usporg)
2 Column: Revision Bulletin Official December 1, 2017 Diltiazem 1 21-mm 15-cm; 17-µm packing L1 Diltiazem Hydrochloride Extended- Flow rate: 03 ml/min Injection volume: 20 µl Release Capsules System suitability Sample: Standard DEFINITION Suitability requirements Diltiazem Hydrochloride Extended-Release Capsules contain Tailing factor: NMT 20 NLT 900% and NMT 1100% of the labeled amount of Relative standard deviation: NMT 10% diltiazem hydrochloride (C 22H 26N 2O 4S HCl) Analysis Samples: Standard and Sample IDENTIFICATION Calculate the percentage of the labeled amount of dil- A The UV-Vis spectrum of the major peak of the Sample tiazem hydrochloride (C 22H 26N 2O 4S HCl) in the por corresponds to that of the Standard, as tion of Capsules taken: obtained in the Assay B The retention time of the major peak of the Sample Result = (r U/r S) (C S/C U) 100 corresponds to that of the Standard, as obtained in the Assay r U = peak response of diltiazem from the Sample ASSAY r S = peak response of diltiazem from the Standard PROCEDURE Solution A: 079 g/l of ammonium bicarbonate in C S = concentration of USP Diltiazem Hydrochloride water Adjust with diluted ammonia or acetic RS in the Standard (mg/ml) acid to a ph of 80 C U = nominal concentration of diltiazem Solution B: Acetonitrile hydrochloride in the Sample Mobile phase: See Table 1 (mg/ml) Acceptance criteria: 900% 1100% Table 1 Solution A Solution B PERFORMANCE TESTS (min) (%) (%) Change to read: DISSOLUTION 711 For products labeled for dosing every 12 h Test 1: If the product complies with this test, the la beling indicates that it meets USP Dis Test s: 3, 9, and 12 h Diluent: Acetonitrile and water (40:60) Standard : 005 mg/ml of USP Diltiazem Hy- drochloride RS in Diluent Sample : Sample per Dis 711 Di- Sample stock : Nominally 05 mg/ml of dilthat tiazem hydrochloride from the Capsules in Diluent prepared of the Standard as follows Transfer a portion of finely powdered Tolerances: See contents of NLT 20 Capsules to a suitable volumetric flask Add Diluent equivalent to 80% of the flask vol- Table 2 ume, mechanically shake for 30 min, and sonicate for 60 min Dilute with the Diluent to volume Centrifuge and use the supernatant Sample : Nominally 005 mg/ml of diltiazem hydrochloride prepared in Diluent from Sample stock NLT 70 Chromatographic system (See Chromatography 621, System Suitability) Mode: LC Detector: UV 240 nm For Identification A, use a diode array detector in the range of nm tance Test 4: If the product complies with this test, the labeling indicates that it meets USP Dis Test 4 s: 4, 8, 12, and 24 h Sample : Sample per Dis 711 Dilute Tolerances: See Table The United States Pharmacopeial Convention All Rights Reserved
3 2 Diltiazem Official December 1, 2017 Table 3 s: 1, 4, 10, and 15 h Sample : Sample per Dis 711 Dilute 24 NLT 80 Tolerances: See Table 6 Table 6 Test 5: If the product complies with this test, the la- beling indicates that it meets USP Dis Test 5 Medium: 005 M phosphate buffer, ph 72; 900 ml Apparatus 2: 50 rpm s: 1, 3, and 8 h NLT 80 Sample : Sample per Dis 711 Di- times specified conform to Dis 711, Accepthat of the Standard tance Tolerances: See Table 4 Test 3: If the product complies with this test, the labeling indicates that it meets USP Dis Test 3 Table 4 Medium: 01 N hydrochloric acid; 900 ml s: 6, 12, 18, 24, and 30 h 1 NMT NLT 80 Sample : Sample per Dis 711 Dilute Tolerances: See Table 7 Test 10: If the product complies with this test, the Table 7 labeling indicates that it meets USP Dis Test 10 Buffer: Dissolve 71 g of anhydrous dibasic sodium phosphate in 1000 ml of water, and adjust with phosphoric acid to a ph of Medium: Buffer; 900 ml 24 NLT 70 s: 1, 6, 9, and 24 h 30 NLT 85 Sample : Sample per Dis 711 Ditance times specified conform to Dis 711, Acceplute Test 6: If the product complies with this test, the la- Tolerances: See Table 5 beling indicates that it meets USP Dis Test 6 Table 5 s: 2, 4, 8, 12, and 16 h 1 NMT 10 Sample : Sample per Dis 711 Di NLT 80 Tolerances: See Table 8 Table 8 tance For products labeled for dosing every 24 h 2 NMT 25 Test 2: If the product complies with this test, the la beling indicates that it meets USP Dis Test The United States Pharmacopeial Convention All Rights Reserved
4 Official December 1, 2017 Diltiazem 3 Table 8 (Continued) Test 9: If the product complies with this test, the la- beling indicates that it meets USP Dis Test [NOTE Perform the test separately in each of the two 12 NLT 70 media] 16 NLT 80 Medium 1: 01 N hydrochloric acid; 900 ml Medium 2: Simulated intestinal fluid TS, prepared without enzyme and adjusted to a ph of 75 ± 01; 900 ml Apparatus 2: 75 rpm tance for Medium 1: 2 h Test 7: If the product complies with this test, the la- s for Medium 2: 2, 12, 18, and 24 h beling indicates that it meets USP Dis Test 7 Buffer: Transfer 115 ml of acetic acid to a 10-L volu- metric flask, dilute with water to volume, and mix (Solution A) Transfer 1654 g of anhydrous sodium Sample : Sample per Dis 711 Diacetate to a 10-L volumetric flask, dilute with water to volume, and mix (Solution B) Mix 4410 ml of Solution A with 1590 ml of Solution B Adjust, if nec- Tolerances: See Table 11 essary, with the addition of Solution A or Solution B to a ph of 42 ± 005 Medium: Buffer; 900 ml Table 11,, s: 1, 4, 10, and 15 h Medium 1 Medium 2 (%) Sample : Sample per Dis 711 Di- 18 NLT NLT 80 Tolerances: See Table 9 Table 9 Test 11: If the product complies with this test, the labeling indicates that it meets USP Dis Test 1 NMT Medium: 01 N hydrochloric acid; 900 ml NLT 80 s: 1, 6, 12, and 18 h Sample : Sample per Dis 711 Ditance Test 8: If the product complies with this test, the la- beling indicates that it meets USP Dis Test 8 Tolerances: See Table 12 s: 1, 4, 10, and 15 h Table 12 1 NMT 10 Sample : Sample per Dis 711 Di Tolerances: See Table NLT 85 Table 10 tance Test 12: If the product complies with this test, the labeling indicates that it meets USP Dis Test Proceed as directed for Extended-Release Dosage Forms in Procedure, Apparatus 1 and Apparatus 2 15 NLT The United States Pharmacopeial Convention All Rights Reserved
5 4 Diltiazem Official December 1, 2017 Table 15 s: 2, 8, 14, and 24 h Sample : Sample per Dis 711 Dilute NLT NLT 80 Tolerances: See Table 13 Table 13 tance Test 15: If the product complies with this test, the 2 NMT 20 labeling indicates that it meets USP Dis Test Proceed as directed for Extended-Release Dosage 14 NLT 65 Forms in Procedure, Apparatus 1 and Apparatus 2 24 NLT 80 Medium: 005 M phosphate buffer, ph 75; 900 ml Apparatus 2: 75 rpm s: 2, 4, 8, 12, and 16 h times specified conform to Dis 711, Accepin Medium tance Test 13: If the product complies with this test, the Sample : Sample per Dis 711 Dilabeling indicates that it meets USP Dis Test 13 Proceed as directed for Extended-Release Dosage Forms in Procedure, Apparatus 1 and Apparatus 2 Tolerances: See Table 16 Table 16 s: 2, 8, 14, and 24 h 2 NMT 25 Sample : Sample per Dis 711 Dilute NLT 70 Tolerances: See Table NLT 80 Table 14 tance 2 NMT 20 Test 16: If the product complies with this test, the labeling indicates that it meets USP Dis Test NLT 80 Medium, Apparatus 2, s, Standard, and Sample : Proceed as directed for Test 3 Detector: UV 238 nm Tolerances: See Table 17 Test 14: If the product complies with this test, the Table 17 labeling indicates that it meets USP Dis Test 14 Proceed as directed for Extended-Release Dosage Forms in Procedure, Apparatus 1 and Apparatus 2 Medium: 01 N hydrochloric acid; 900 ml s: 6, 12, 18, 24, and 30 h NLT NLT 80 Sample : Sample per Dis 711 Di- Tolerances: See Table 15 tance Test 17: If the product complies with this test, the labeling indicates that it meets USP Dis Test The United States Pharmacopeial Convention All Rights Reserved
6 Official December 1, 2017 Diltiazem 5 Medium: 01 N hydrochloric acid; 900 ml Calculate the percentage of the labeled amount of, with wire helix sinkers diltiazem hydrochloride (C 22H 26N 2O 4S HCl) s: 6, 12, and 30 h dissolved at each time point i: Detector: UV 238 nm Result 1 = C 1 V (1/L) 100 Sample : Dilute with Medium, if necessary, to a concentration that is similar to that of the Standard Result 2 = [(C 2 V) + (C 1 V S)] (1/L) 100 Blank: Medium Tolerances: See Table 18 Result 3 = {(C 3 V ) + [(C 2 + C 1) V S]} (1/L) 100 Table 18 Result 4 = {(C 4 V) + [(C 3 + C 2 + C 1) V S]} (1/L) 100 C i = concentration of diltiazem hydrochloride in the Sample withdrawn at the specified time point (mg/ml) 30 NLT 80 V L = volume of Medium, 900 ml = label claim (mg/capsule) V S = volume of the Sample withdrawn at each time point (ml) Tolerances: See Table 19 (RB 10-Oct-2017) Test 18: If the product complies with this test, the Table 19 labeling indicates that it meets USP Dis Test 18 Point (i) 1 2 NMT 20 s: 2, 4, 8, and 12 h Standard stock : 028 mg/ml of USP Dil NLT 80 tiazem Hydrochloride RS prepared as follows To a suitable amount of USP Diltiazem Hydro- chloride RS in a suitable volumetric flask, add Medium to 50% of the volume of the flask and soni- times specified conform to Dis 711, Accepcate for 5 min to dissolve Dilute with Medium to tance (RB 1-Dec-2017) volume UNIFORMITY OF DOSAGE UNITS 905 : Meet the Standard : 0014 mg/ml of USP Diltiazem requirements Hydrochloride RS from the Standard stock Sample : At the times specified, withdraw IMPURITIES 10 ml of the under test Replace the aliquots withdrawn for analysis with equal volumes of Change to read: fresh portions of Medium maintained at 37 Pass the through a PVDF filter of 045-µm pore size ORGANIC IMPURITIES Discard the first 2 ml of filtrate Dilute with Medium Solution A, Solution B, Mobile phase, Diluent, and to a concentration that is similar to that of the Stan- Chromatographic system: Proceed as directed in the dard Assay Analysis Standard : 25 µg/ml each of USP Desacetyl Samples: Standard and Sample Diltiazem Hydrochloride RS and USP Diltiazem Hydro- Calculate the concentration of diltiazem hydrochlo- chloride RS in Diluent ride (C 22H 26N 2O 4S HCl) in the sample withdrawn Sample : Nominally 05 mg/ml of diltiazem from the vessel at each time point i: hydrochloride from the Capsules in Diluent prepared as follows Transfer a portion of the finely powdered contents Result = (A U/A S) C S D of NLT 20 Capsules to a suitable volumetric flask Add Diluent equivalent to 80% of the flask volume, A U = absorbance of diltiazem from the Sample mechanically shake for 30 min, and sonicate for 60 at each time point min Dilute with Diluent to volume Centrifuge and use A S = absorbance of diltiazem from the Standard the supernatant System suitability C S = concentration of USP Diltiazem Hydrochloride Sample: Standard RS in the Standard (mg/ml) [NOTE For relative retention times see Table 20 (RB 1- D = dilution factor of the Sample Dec-2017)] Suitability requirements Re: NLT 20 between desacetyl diltiazem and diltiazem 2017 The United States Pharmacopeial Convention All Rights Reserved
7 g g Revision Bulletin 6 Diltiazem Official December 1, 2017 Relative standard deviation: NMT 30% Table 20 (RB 1-Dec-2017) (Continued) Analysis Relative Acceptance Samples: Standard and Sample Retention Criteria, Calculate the percentage of desacetyl diltiazem hy- Name NMT (%) drochloride (RB 10-Oct-2017) in the portion of Capsules Diltiazem related compound C d taken: 058 b, Diltiazem related compound D e 061 b, Result = (r U/r S) (C S/C U) 100 Diltiazem related compound E 066 b,f Desacetyl g diltiazem (RB 1-Dec-2017) r U = peak response of desacetyl diltiazem from the Diltiazem related compound A h Sample b, (RB 1-Dec-2017) 083 r S = peak response of desacetyl diltiazem from the Diltiazem related compound B i Standard b, (RB 1-Dec-2017) 089 C S = concentration of USP Desacetyl Diltiazem Diltiazem 10 Hydrochloride RS in the Standard Any individual unspecified impurity 02 (µg/ml) C U = nominal concentration of diltiazem Total impurities 20 hydrochloride in the Sample (µg/ml) a (2S,3S)-5-(2-Aminoethyl)-3-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1, Calculate the percentage of any individual unspecified 5-benzothiazepine-4(5H)-one b impurity in the portion of Capsules taken: These are impurities related to the drug substance They are not to be reported for the drug product and should not be included in the total Result = (r U/r S) (C S/C U) 100 impurities c (2S,3S)-3-Hydroxy-2-(3-methoxyphenyl)-5-(2-(methylamino)ethyl)-2,3- r U dihydrobenzo[b][1,4]thiazepin-4(5h)-one = peak response of each unspecified impurity d (2S,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-hydroxyphenyl)-4-oxo-2,3,4,5- from the Sample tetrahydro-1,5-benzothiazepin-3-yl acetate r S = peak response of diltiazem from the Standard e (2S,3S)-2-(4-Methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3,4,5- tetrahydro-1,5-benzothiazepine-3-yl acetate f C S = concentration of USP Diltiazem Hydrochloride (2S,3S)-3-Hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5- RS in the Standard (µg/ml) benzothiazepine-4(5h)-one C U = nominal concentration of diltiazem d-cis-3-hydroxy-2,3-dihydro-5-[2-dimethylamino)ethyl]-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one The acceptance criteria for this hydrochloride in the Sample (µg/ml) impurity is based on the hydrochloride form Acceptance criteria: See Table 20 (RB 1-Dec-2017) Disre- h (RB 1-Dec-2017) (2R,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-methoxyphenyl)-4- gard limit: 005% oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-3-yl acetate i (RB 1-Dec-2017) (2S,3S)-2-(4-Methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1, 5-benzothiazepine-3-yl acetate Table 20 (RB 1-Dec-2017) Relative Acceptance ADDITIONAL REQUIREMENTS Retention Criteria, PACKAGING AND STORAGE: Preserve in tight containers Name NMT (%) Store at controlled room temperature LABELING: The labeling indicates the Dis test with Diltiazem related compound H b 044 which the product complies a, Diltiazem related compound G c 052 b, a (2S,3S)-5-(2-Aminoethyl)-3-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1, 5-benzothiazepine-4(5H)-one Change to read: b These are impurities related to the drug substance They are not to be reported for the drug product and should not be included in the total USP REFERENCE STANDARDS 11 impurities USP Desacetyl Diltiazem Hydrochloride RS c (2S,3S)-3-Hydroxy-2-(3-methoxyphenyl)-5-(2-(methylamino)ethyl)-2,3- d-cis-3-hydroxy-2,3-dihydro-5-[2-dimethylamidihydrobenzo[b][1,4]thiazepin-4(5h)-one no)ethyl]-2-(p-methoxyphenyl)-1,5-benzothiazepind tetrahydro-1,5-benzothiazepin-3-yl (2S,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-hydroxyphenyl)-4-oxo-2,3,4,5- acetate 4(5H)-one hydrochloride (RB 1-Dec-2017) C 20H 24N 2O 3S HCl e (2S,3S)-2-(4-Methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3,4,5- tetrahydro-1,5-benzothiazepine-3-yl acetate USP Diltiazem Hydrochloride RS f (2S,3S)-3-Hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5- benzothiazepine-4(5h)-one d-cis-3-hydroxy-2,3-dihydro-5-[2-dimethylamino)ethyl]-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one The acceptance criteria for this impurity is based on the hydrochloride form h (RB 1-Dec-2017) (2R,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-methoxyphenyl)-4- oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-3-yl acetate i (RB 1-Dec-2017) (2S,3S)-2-(4-Methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1, 5-benzothiazepine-3-yl acetate 2017 The United States Pharmacopeial Convention All Rights Reserved
contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Diltiazem Hydrochloride Extended-Release Capsules Type of Posting Notice of Intent to Revise Posting Date 25 May 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical
More informationTramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance
Tramadol Hydrochloride Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 27 May 2016 Official Date 01 Jun 2016 Expert Committee Chemical Medicines Monographs 2 Reason for Revision
More informationThe Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.
Nitrofurantoin Capsules Type of Posting Revision Bulletin Posting Date 28 Dec 2018 Official Date 01 Jan 2019 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance
More informationShould you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or
Divalproex Sodium Delayed-Release Capsules Type of Posting Revision Bulletin Posting Date 29 July 2016 Official Date 01 Aug 2016 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance
More informationQuetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance
Quetiapine Tablets Type of Posting Revision Bulletin Posting Date 25 Sep 2015 Official Date 01 Nov 2015 Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance In accordance with
More informationcontents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.
Metoprolol Succinate Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 26 Jan 2018, revised 12 Feb 2018 1 Targeted Official Date To Be Determined, Revision Bulletin Expert
More informationTelmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date
Telmisartan and Hydrochlorothiazide Tablets Type of Posting Revision Bulletin Posting Date 26 Jan 2018 Official Date 01 Feb 2018 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance
More informationRevision Bulletin 23 Feb Mar 2018 Chemical Medicines Monographs 3 Compliance
Esomeprazole Magnesium Delayed-Release Capsules Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 23 Feb 2018 01 Mar 2018 Chemical Medicines Monographs 3
More informationThis revision also necessitates a change in the table numbering in the test for Organic Impurities.
Methylphenidate Hydrochloride Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 27 Jul 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical
More informationShould you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or
Duloxetine Delayed-Release Capsules Type of Posting Revision Bulletin Posting Date 28 July 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance
More informationRevision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3
Oxybutynin Chloride Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 28 Jul 2017 01 Aug 2017 Chemical Medicines Monographs 3 Compliance
More informationCompliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or
Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 30 Mar 2018 Official Date 01 Apr 2018 Expert Committee Chemical Medicines Monographs 3 Reason for Revision Compliance In accordance
More informationShould you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison ( or
Estradiol Transdermal System Type of Posting Revision Bulletin Posting Date 27 Jan 2017 Official Date 01 Feb 2017 Expert Committee Chemical Medicines Monographs 5 Reason for Revision Compliance In accordance
More informationCompliance. Minor editorial changes have been made to update the monograph to the current USP style.
Nifedipine Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 28 Jul 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance
More informationMinor editorial changes have been made to update the monograph to the current USP style.
Nifedipine Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 29 Sep 2017 Official Date 01 Oct 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance
More informationThe Tacrolimus Capsules Revision Bulletin supersedes the currently official monograph.
Tacrolimus Capsules Type of Posting Revision Bulletin Posting Date 27 Jul 2018 Official Date 01 Aug 2018 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance with
More informationcontents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Estradiol Transdermal System Type of Posting Notice of Intent to Revise Posting Date 28 Sep 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical Medicines Monographs
More informationPharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA
818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA Following is a list of errata and corrections to USP NF. The page number indicates where the item is found and in which official or
More informationShould you have any questions, please contact Ravi Ravichandran, Principal Scientific Liaison ( or
Fluticasone Propionate and Salmeterol Inhalation Powder Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 13 Dec 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More informationINTERIM REVISION ANNOUNCEMENT
INTERIM REVISION ANNOUNCEMENT In this section readers will find the following: The list of new USP Reference Standards that have become available The list of assays or tests that are adopted but held in
More informationCHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
132 CHAPTER 6 DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF PARACETAMOL, TRAMADOL HYDROCHLORIDE AND DOMPERIDONE IN A COMBINED DOSAGE FORM 6.1 INTRODUCTION
More informationTENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)
June 2010 TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010) This monograph was adopted at the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical
More informationRITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)
July 2012 RITONAVIRI COMPRESSI RITONAVIR TABLETS Final text for addition to The International Pharmacopoeia (July 2012) This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications
More informationARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS
December 2009 ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) This monograph was adopted at the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical
More informationRebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica
Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica This
More informationASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC
ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC METHOD APPROVALS Norvin Pharma Inc. Author Analytical Laboratory Approver Analytical Laboratory Group Leader Approver Manager Quality Control Chemistry
More informationINTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS
RESTRICTED INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS DRAFT FOR COMMENT Please address any comments you may have on this document, by 12 July 2006, to Dr S. Kopp, Quality Assurance and
More informationTitle Revision n date
A. THIN LAYER CHROMATOGRAPHIC TECHNIQUE (TLC) 1. SCOPE The method describes the identification of hydrocortisone acetate, dexamethasone, betamethasone, betamethasone 17-valerate and triamcinolone acetonide
More informationAripiprazole (USP) We have followed the current Aripiprazole USP monograph (USP38-NF33):
Aripiprazole (USP) Aripiprazole is an atypical antipsychotic, and it is a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder,
More information[NOTE The relative retention times for calcitonin salmon and calcitonin salmon related compound A Change to read:
. Mode: Revision Bulletin Official April 1, 2012 Calcitonin Salmon 1 LC Calcitonin Salmon Detector: UV 220 nm Column: 4.6-mm 25-cm; packing L1 Column temperature: 65 Flow rate: 1 ml/min Injection volume:
More informationCYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)
August 2015 Document for comment 1 2 3 4 5 CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA (AUGUST 2015) DRAFT FOR COMMENT 6 Should you have any comments
More informationBRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Identification B Identification C + + +
BRIEFING Edetate Calcium Disodium, USP 29 page 779. The Japanese Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Edetate Calcium Disodium
More informationChange to read: BRIEFING
BRIEFING Dibasic Calcium Phosphate Dihydrate, USP 29 page 359. The Japanese Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Dibasic
More informationTenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)
C 19 H 30 N 5 O 10 P. C 4 H 4 O 4 Relative molecular mass. 635.5. Chemical names. bis(1-methylethyl) 5-{[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}-5-oxo-2,4,6,8-tetraoxa-5-λ 5 - phosphanonanedioate
More informationLEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT
January 2012 RESTRICTED DRAFT PROPOSAL FOR The International Pharmacopoeia LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS (January 2012) DRAFT FOR COMMENT This document was provided by a quality control expert.
More informationResidue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.
Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Aspartame This monograph was also published in: Compendium of Food Additive
More informationCHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
51 CHAPTER 2 SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY-INDICATING RP-HPLC METHOD 2.1 INTRODUCTION OF DOSAGE FORM
More informationDevelopment and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1736-1744, Oct-Dec 2013 Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin
More informationHPLC to UHPLC Transfer of USP Method for Amlodipine Besylate Using the Agilent 1290 Infinity II LC
HPLC to UHPLC Transfer of USP Method for Amlodipine Besylate Using the Agilent 129 Infinity II LC Application Note Small Molecule Pharmaceuticals Authors Gerd Vanhoenacker, Mieke Steenbeke, Koen Sandra,
More informationUSP Method Transfer of Ziprasidone HCl from HPLC to UPLC
Mia Summers and Kenneth J. Fountain Waters Corporation, Milford, MA, USA APPLICATION BENEFITS Updating USP Methods from HPLC to UPLC using sub-2 µm columns 85% decrease in analysis time, faster throughput
More informationBRIEFING. Nonharmonized attributes: Identification, Heavy metals, Characters, Labeling, Bacterial endotoxins, Sterility, Storage.
BRIEFING Citric Acid, Anhydrous, page 872 of PF 28(3) [May June 2002]. The European Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the
More information» Monohydrate Citric Acid contains one molecule of water of hydration. It contains not less than 99.5 percent and not more than 100.
BRIEFING Citric Acid, Monohydrate. The European Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Citric Acid, Monohydrate monograph,
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION
http://www.rasayanjournal.com Vol.4, No.1 (2011), 165-171 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR AND ITS PHARMACEUTICAL FORMULATION V. Kalyana Chakravarthy * and
More informationAnalysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column
Application Note Pharmaceutical and Food Testing Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column Author Lu Yufei Agilent Technologies, Inc. Abstract A liquid chromatographic
More informationDRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS
December 2015 Draft document for comment 1 2 3 4 5 6 DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS (December 2015) REVISED DRAFT FOR COMMENT Should
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(1):138-144 Simultaneous RP HPLC determination of Latanoprost
More informationCHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG
CHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE IN TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG ANALYTICAL METHOD VALIDATION REPORT FOR ASSAY 43 2.1 Introduction Analytical
More informationSULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)
September 2010 RESTRICTED SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010) REVISED DRAFT FOR COMMENT This document was provided by a quality
More informationMONOGRAPHS (USP) Saccharin Sodium
Vol. 31(4) [July Aug. 2005] HARMONIZATION 1225 MONOGRAPHS (USP) BRIEFING Saccharin Sodium, USP 28 page 1745 and page 612 of PF 31(2) [Mar. Apr. 2005]. The United States Pharmacopeia is the coordinating
More informationPAPRIKA EXTRACT SYNONYMS DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS
PAPRIKA EXTRACT Prepared at the 77 th JECFA, published in FAO JECFA Monographs 14 (2013), superseding tentative specifications prepared at the 69 th JECFA (2008). An ADI of 0-1.5 mg/kg bw was allocated
More informationIJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:
IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Method development and validation of tenofovir disoproxil fumerate and emtricitabine in combined tablet
More informationUSP purity analysis of pravastatin sodium using the Agilent 1120 Compact LC
USP purity analysis of pravastatin sodium using the Agilent 1120 Compact LC Application Note Manufacturing QA/QC Authors Syed S. Lateef, Siji Joseph Agilent Technologies Bangalore, India 500 400 Pravastatin
More informationA simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical dosage form
IJPAR Vol.4 Issue 1 Jan-Mar-2015 Journal Home page: ISSN: 2320-2831 Research article Open Access A simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical
More informationZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)
September 2006 RESTRICTED ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006) This document was provided by a contracted quality control laboratory.
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(1):6-10 ISSN: 0976-8688 CODEN (USA): PSHIBD Validated RP-HPLC method for simultaneous estimation of metformin hydrochloride
More informationMethotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.
Browse: British Pharmacopoeia 2013 British Pharmacopoeia Volume I & II Monographs: Medicinal and Pharmaceutical Substances Methotrexate Methotrexate General Notices (Ph. Eur. monograph 0560) C 20 H 22
More informationDevelopment and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (11):236-242 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION
http://www.rasayanjournal.com Vol.4, No.3 (2011), 666-672 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR IN BULK AND ITS PHARMACEUTICAL FORMULATION V.Kalyan Chakravarthy*
More informationANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DILTIAZEM HYDROCHLORIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP- HPLC
Research Communication ISSN 2394-2789(Print) e-issn 2394-2797(Online) ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DILTIAZEM HYDROCHLORIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY
More informationResearch Article DEVOLOPMENT OF RP-HPLC METHOD AND IT S VALIDATION FOR SIMULTANEOUS ESTIMATION OF SITAGLIPTIN AND METFORMIN
Research Article DEVOLOPMENT OF RP-HPLC METHOD AND IT S VALIDATION FOR SIMULTANEOUS ESTIMATION OF SITAGLIPTIN AND METFORMIN Sumithra M 1, Shanmugasudaram MRP, Sankar ASK and Niharika MRS Department of
More informationValidation of Changes to the USP Assay Method for Ibuprofen Tablets
Validation of Changes to the USP Assay Method for Ibuprofen Extraction and Filtration Techniques Lynn Massad, Pam Anderson, James Ward, Philip Burns, and Ranga Velagaleti* This article discusses changes
More informationMETHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Ramalakshmi et al. SJIF Impact Factor 6.647 Volume 7, Issue 2, 1010-1018 Research Article ISSN 2278 4357 METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC
More informationU.S. Pharmacopeia Methods for HPLC
U.S. Pharmacopeia Methods for PLC Technical ote Applications in accordance with U.S. Pharmacopeia Methods in USP-PF(Pharmacopoeial Forum) online is available on our website. For more information, please
More informationMONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005]
616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005] the recorder. The substances are eluted in the following order: o-toluenesulfonamide, p-toluenesulfonamide, and caffeine. The test is not valid unless the
More informationARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia
February 2012 ARTENIMOLUM ARTENIMOL Adopted revised text for addition to The International Pharmacopoeia This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications for Pharmaceutical
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ASSAY AND DISSOLUTION OF METOPROLOL SUCCINATE EXTENDED RELEASE TABLETS
Innovare Academic Sciences International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 6, Issue 5, 2014 Original Article DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ASSAY AND
More informationCOMMENTARY TO USP31 - NF26
Revision proposals published in Pharmacopeial Forum often elicit public comments that are forwarded to the appropriate Expert Committee for review and response. In accordance with the Rules and Procedures
More informationSTANDARD OPERATING PROTOCOL (SOP)
1 STANDARD PERATING PRTCL (SP) Subject: To determine the Contents of isoflavone in soybean products by HPLC Analysis Project/Core No.: Core B Total 9 Pages SP No.: CB0102 Modified Date: 05/15/01 BTANICAL
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(2): 294-299 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationNew RP - HPLC Method for the Determination of Valproic acid in Human Plasma
New RP - HPLC Method for the Determination of Valproic acid in Human Plasma C.Venkata Nagendra Prasad 1, Ch.Santhosh Kumari a, B.Srinivasa Reddy 1 and Prof. J. Sriramulu 2 1 Sree Dattha Institute of Pharmacy,
More informationRP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol. 3, No.2, pp 605-609, April-June 2011 RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem
More informationNational Standard of the People s Republic of China. National food safety standard. Determination of pantothenic acid in foods for infants and
National Standard of the People s Republic of China GB 5413.17 2010 National food safety standard Determination of pantothenic acid in foods for infants and young children, milk and milk products Issued
More information10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.:
10 Sulfaquinoxaline N N H N O S O NH 2 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: 300.33 CAS No.: 59-40-5 Outline of sulfaquinoxaline Sulfaquinoxaline is light yellow to brownish
More informationCLINDAMYCIN PALMITATE
February 2018 Document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 CLINDAMYCIN PALMITATE POWDER FOR ORAL
More informationANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS
Research Article N. Bala Krishna, IJPRBS, 2013; Volume 2(1): 63-77 ISSN: 2277-8713 IJPRBS N.BALAA KRISHNA, Dr. M.V.V NAGESWARA REDDY IJPRBS-QR CODE PAPER-QR CODE DEVELOPMENT OF NEW ANALYTICAL TECHNIQUES
More informationDraft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution
August 2015 Draft document for comment 1 2 3 4 5 6 Draft monograph for inclusion in The International Pharmacopoeia Dextromethorphani solutionum peroralum - Dextromethorphan oral solution (August 2015)
More informationNOVEL RP-HPLC METHOD. B.Lakshmi et a. concentration range KEY INTRODUCTION. Diltiazem is used to. . It works by of contractionn of the. (dilate).
B.Lakshmi et a ISSN-2319-2119 al, The Experiment, January. 2013 Vol..6(4), 365-371 A NOVEL RP-HPLC METHOD FOR THE DETERMINATION OF DILTIAZEM IN PHARMACEUTICAL DRUG PRODUCTS ABSTRACT High resolution RP-HPLC
More information(ACE) inhibitor class that is primarily used in cardiovascular. conditions. Lisinopril was introduced into therapy in the early
107 CHAPTER 5 METHODDEVOLOPMENT FOR SIMULTANEOUS DETERMINATION OF LISINOPRIL AND HYDROCHLOROTHIAZIDE RELATED IMPURITIES IN LISINOPRIL AND HYDROCHLOROTHIAZIDE COMBINED TABLET DOSAGE FORMS USING HPLC 108
More informationComparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation
Oriental Journal of Chemistry Vol. 24(2), 537-544 (2008) Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation P.N. DALVI,
More informationLutein Esters from Tagetes Erecta
Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Lutein Esters from Tagetes Erecta This monograph was also published in: Compendium
More informationRP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form
RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form S. LAVANYA* 1, SK. MANSURA BEGUM 1, K. NAGAMALLESWARA RAO 2, K. GAYATHRI DEVI 3 Department of pharmaceutical
More informationThe present work was aimed at developing a validated RP-UPLC method for simultaneous estimation of Sitagliptin (Anti
Titus Darsi*et al. /International Journal of Pharmacy & Technology ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com ANALYTICAL METHOD DEVELOPMENT AND VALIDATION
More informationJ Pharm Sci Bioscientific Res (4): ISSN NO
Development and Validation of Analytical Methods for Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in their Combined Marketed Dosage form ABSTRACT: Nikhilkumar Patel, Gurjit Kaur,
More informationHyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.
International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik
More informationF. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract
JJC Jordan Journal of Chemistry Vol. 4 No.4, 2009, pp. 357-365 Development and Validation of Analytical Method for Fluconazole and Fluconazole Related Compounds (A, B, and C) in Capsule Formulations by
More informationAnalytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)
Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products) The target compound to be determined is 2, 4, 5-T. 1. Instrument Liquid Chromatograph-tandem mass spectrometer (LC-MS/MS)
More informationDraft proposal for The International Pharmacopoeia
April 2012 RESTRICTED SULFAMETHOXAZOLE AND TRIMETHOPRIM INTRAVENOUS INFUSION Draft proposal for The International Pharmacopoeia (April 2012) DRAFT FOR COMMENT This document was provided by a quality control
More informationEMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED EMTRICITABINE AND TENOFOVIR TABLETS Draft proposal for The International Pharmacopoeia (September2010) REVISED DRAFT FOR COMMENT This document was provided by a quality control
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF TRAMADOL IN PURE AND PHARMACEUTICAL FORMULATIONS
Int. J. Chem. Sci.: 10(4), 2012, 2039-2047 ISSN 0972-768X www.sadgurupublications.com DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF TRAMADOL IN PURE AND PHARMACEUTICAL FORMULATIONS
More informationFLUNITRAZEPAM Latest Revision: January 24, 2006
FLUNITRAZEPAM Latest Revision: January 24, 2006 1. SYNONYMS CFR: Flunitrazepam CAS #: 1622-62-4 Other Names: 5-(2-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H- 1,4-benzodiazepin-2-one Flunitrax Hipnosedon
More informationRP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 22, No. 7 (2010), 5067-5071 RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms A. LAKSHMANA RAO*, G. TARAKA RAMESH and J.V.L.N.S. RAO Department of Pharmaceutical
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF ANTIRETROVIRAL DRUGS IN TABLET DOSAGE FORMS
Int. J. Chem. Sci.: 14(4), 2016, 2461-2466 ISSN 0972-768X www.sadgurupublications.com DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF ANTIRETROVIRAL DRUGS IN TABLET DOSAGE FORMS K. PARAMESWARA
More informationDevelopment and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets
Journal of PharmaSciTech 0; ():- Research Article Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets * Sayyed Hussain,
More informationBRIEFING Assay + + +
BRIEFING Sodium Starch Glycolate, NF 22 page 2933 and page 3202 of PF 22(6) [Nov. Dec. 1996]. The United States Pharmacopeia is the coordinating pharmacopeia for the international harmonization of the
More informationPROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)
July 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012) PROPOSED REVISION FOR COMMENT The background
More informationIsocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol in Pure and Formulations
Human Journals Research Article October 2015 Vol.:4, Issue:3 All rights are reserved by Rambabu K et al. Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol
More information1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE
1 out of 8 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE This monograph was also published in: Compendium of Food
More informationISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine
More informationABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)
August 2012 RESTRICTED ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012) Draft for comment This document was provided by a quality control expert. Should you have
More informationRP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF CITICOLINE AND PIRACETAM IN PHARMACEUTICAL DOSAGE FORM
Page3639 Indo American Journal of Pharmaceutical Research, 2015 ISSN NO: 2231-6876 RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF CITICOLINE AND PIRACETAM IN PHARMACEUTICAL
More information